Abstract
In this retrospective analysis, 30 patients with acute GVHD (aGVHD) and 32 patients with chronic GVHD (cGVHD) treated with extracorporeal photopheresis (ECP) performed by the COBE Spectra System were evaluated. After 3 months of ECP treatment, a CR and PR were observed in 9 (30%) and 6 (20%) patients with aGVHD and in 2 (6%) and 12 (38%) patients with cGVHD. In 16 (53%) patients with aGVHD and 9 (28%) with cGVHD ECP treatment was already stopped after 3 months. One (3%) patient with aGVHD and 7 (22%) patients with cGVHD received new additional immunosuppressive therapy started during the first 3 months of ECP treatment and were classified as ‘nonresponder’ with regard to ECP. Of these patients a PR was achieved in one patient with aGVHD and in three patients with cGVHD. Steroids could be tapered by ⩾50 in 83% of patients with aGVHD and in 29% of patients with cGVHD after 3 months of ECP treatment. Patients with aGVHD achieving a CR or PR showed a significant improved OS after allo-SCT (P=0.019). ECP is associated with significant response rates and successful reduction of steroids in patients with GVHD.
Similar content being viewed by others
References
Wolff D, Schleuning M, Harsdorf S, von, Bacher U, Gerbitz A, Stadler M et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011; 17: 1–17.
Knobler R, Barr ML, Couriel DR, Ferrara JLM, French LE, Jaksch P et al. Extracorporeal photopheresis: past, present, and future. J Am Acad Dermatol 2009; 61: 652–665.
Gatza E, Rogers CE, Clouthier SG, Lowler KP, Tawara I, Liu C et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 2008; 112: 1515–1521.
Greinix HT, Socié G, Bacigalupo A, Holler E, Edinger MG, Apperley JF et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant 2006; 38: 265–273.
Holtick U, Marshall SR, Wang X, Hilkens CMU, Dickinson AM . Impact of psoralen/UVA-treatment on survival, activation, and immunostimulatory capacity of monocyte-derived dendritic cells. Transplantation 2008; 85: 757–766.
Perotti C, Del Fante C, Tinelli C, Viarengo G, Scudeller L, Zecca M et al. Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. Transfusion 2010; 50: 1359–1369.
Dignan FL, Greenblatt D, Cox M, Cavenagh J, Oakervee H, Apperley JF et al. Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD. Bone Marrow Transplant 2012; 47: 824–830.
Perfetti P, Carlier P, Strada P, Gualandi F, Occhini D, van Lint MT et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant 2008; 42: 609–617.
Greinix HT, Knobler RM, Worel N, Schneider B, Schneeberger A, Hoecker P et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 2006; 91: 405–408.
Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 2006; 107: 3074–3080.
Greinix HT, Volc-Platzer B, Kalhs P, Fischer G, Rosenmayr A, Keil F et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 2000; 96: 2426–2431.
Greinix HT, Volc-Platzer B, Rabitsch W, Gmeinhart B, Guevara-Pineda C, Kalhs P et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92: 3098–3104.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.
Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE et al. Bone-Marrow Transplantation. N Engl J Med 1975; 292: 832–843.
Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975; 292: 895–902.
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828.
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.
Schoonemann F . Extracorporeal photopheresis technical aspects. Transfus Apher Sci 2003; 28: 51–61.
Jacob M, Manches O, Drillat P, Richard M, Plumas J, Chaperot L et al. Quality control for the validation of extracorporeal photopheresis process using the Vilbert–Lourmat UV-A irradiation’s system. Transfus Apher Sci 2003; 28: 63–70.
Scrucca L, Santucci A, Aversa F . Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 2007; 40: 381–387.
Scrucca L, Santucci A, Aversa F . Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 2010; 45: 1388–1395.
Messina C, Locatelli F, Lanino E, Uderzo C, Zacchello G, Cesaro S et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003; 122: 118–127.
Dall'Amico R, Messina C . Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Ther Apher 2002; 6: 296–304.
Garban F, Drillat P, Makowski C, Jacob MC, Richard MJ, Favrot M et al. Extracorporeal chemophototherapy for the treatment of graft-versus-host disease: hematologic consequences of short-term, intensive courses. Haematologica 2005; 90: 1096–1101.
Kanold J, Merlin E, Halle P, Paillard C, Marabelle A, Rapatel C et al. Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature. Transfusion 2007; 47: 2276–2289.
González-Vicent M, Ramírez M, Pérez A, Lassaletta A, Sevilla J, Díaz MÁ . Extracorporeal photochemotherapy for steroid-refractory graft-versus-host disease in low-weight pediatric patients. Immunomodulatory effects and clinical outcome. Haematologica 2008; 93: 1278–1280.
González Vicent M, Ramirez M, Sevilla J, Abad L, Díaz MA . Analysis of clinical outcome and survival in pediatric patients undergoing extracorporeal photopheresis for the treatment of steroid-refractory GVHD. J Pediatr Hematol Oncol 2010; 32: 589–593.
Greinix HT, Worel N, Knobler R . Role of extracorporeal photopheresis (ECP) in treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2010; 16: 1747–1748.
Foss FM, DiVenuti GM, Chin K, Sprague K, Grodman H, Klein A et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant 2005; 35: 1187–1193.
Jagasia MH, Savani BN, Stricklin G, Engelhardt B, Kassim A, Dixon S et al. Classic and overlap chronic graft-versus-host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP). Biol Blood Marrow Transplant 2009; 15: 1288–1295.
Flowers MED, Apperley JF, van Besien K, Elmaagacli A, Grigg A, Reddy V et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 2008; 112: 2667–2674.
Scarisbrick JJ, Taylor P, Holtick U, Makar Y, Douglas K, Berlin G et al. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol 2008; 158: 659–678.
Scarisbrick J . Extracorporeal photopheresis: what is it and when should it be used? Clin Exp Dermatol 2009; 34: 757–760.
Couriel D, Hosing C, Saliba R, Shpall EJ, Andelini P, Popat U et al. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work? Biol Blood Marrow Transplant 2006; 12: 37–40.
Rubegni P, Cuccia A, Sbano P, Cevenini G, Carcagnì MR, D'Ascenzo G et al. Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease. Br J Haematol 2005; 130: 271–275.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Daniel Wolff participated in two clinical trials sponsored by Therakos. The other authors declared no conflict of interest.
Additional information
Supplementary Information accompanies the paper on Bone Marrow Transplantation website
Supplementary information
Rights and permissions
About this article
Cite this article
Hautmann, A., Wolff, D., Hahn, J. et al. Extracorporeal photopheresis in 62 patients with acute and chronic GVHD: Results of treatment with the COBE Spectra System. Bone Marrow Transplant 48, 439–445 (2013). https://doi.org/10.1038/bmt.2012.156
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2012.156
- Springer Nature Limited
Keywords
This article is cited by
-
Longitudinal follow-up of response status and concomitant immunosuppression in patients treated with extracorporeal photopheresis for chronic graft versus host disease
Bone Marrow Transplantation (2019)
-
Extracorporeal photopheresis with TC-V in Japanese patients with steroid-resistant chronic graft-versus-host disease
International Journal of Hematology (2018)
-
Cryopreservation as a way to maintain extracorporeal photopheresis regimen for GvHD treatment while circumventing patient temporary inability to undergo apheresis
Bone Marrow Transplantation (2017)
-
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
Leukemia (2015)
-
Extracorporeal photopheresis increases neutrophilic myeloid-derived suppressor cells in patients with GvHD
Bone Marrow Transplantation (2014)